Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 55, 5310-5314, November 15, 1995]
© 1995 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagasu, T.
Right arrow Articles by Garcia, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagasu, T.
Right arrow Articles by Garcia, A. M.

Inhibition of Human Tumor Xenograft Growth by Treatment with the Farnesyl Transferase Inhibitor B956

Takeshi Nagasu, Kentaro Yoshimatsu, Cheryl Rowell, Michael D. Lewis and Ana Maria Garcia1

Department of Cancer Research, Eisai Company, Limited, Tsukuba, 300-26 Japan [T. N., K. Y.], and Eisai Research Institute, Andover, Massachusetts 01810 [C. R., M. D. L., A. M. G.]

ras oncogenes are present in several types of cancers but are most frequently described in colon and pancreatic carcinomas. Consequently, ras is being targeted for drug development as a means to develop therapies for these types of cancer. The ras protein is posttranslationally modified by the addition of a farnesyl group, followed by cleavage of the COOH-terminal 3 amino acids and methylation of the prenylated cysteine. Because the posttranslational addition of farnesyl is obligatory not only for the remaining modifications to take place but also for ras control of cell growth, inhibitors of farnesylation are being developed as potential antitumor agents. In this report, a new peptidomimetic inhibitor of farnesyl transferase is described. This compound, B956, and its methyl ester B1086, inhibit the formation of colonies in soft agar of 14 human tumor cell lines expressing different ras oncogenes at concentrations between 0.2 and 60 µM. Higher concentrations of B956 (10–80 µM) were required to inhibit colony formation by 5 tumor cell lines without ras mutations. B956/B1086 at 100 mg/kg also inhibited tumor growth by EJ-1 human bladder carcinoma, HT1080 human fibrosarcoma, and to a lesser extent by HCT116 human colon carcinoma xenografts in nude mice. Furthermore, inhibition of tumor growth by B956 is shown to be correlated with inhibition of ras posttranslational processing in the tumor. Thus, peptidomimetic inhibitors of ras farnesylation have the potential to be developed as therapy for ras-dependent tumors.

1 To whom requests for reprints should be addressed, at Eisai Research Institute, 4 Corporate Drive, Andover, MA 01810.

Received 7/13/95. Accepted 9/19/95.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. H. Oh, Q. Jin, E. S. Kim, F. R. Khuri, and H.-Y. Lee
Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin-Mediated Increases in Survivin Expression
Clin. Cancer Res., March 1, 2008; 14(5): 1581 - 1589.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
D. A. Haas-Kogan, A. Banerjee, M. Kocak, M. D. Prados, J. R. Geyer, M. Fouladi, T. McKnight, T. Y. Poussaint, A. Broniscer, S. M. Blaney, et al.
Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma
Neuro-oncol, January 1, 2008; 10(3): 341 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
R. Lustig, T. Mikkelsen, G. Lesser, S. Grossman, X. Ye, S. Desideri, J. Fisher, J. Wright, and the New Approaches to Brain Tumor Therapy CNS Cons
Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease
Neuro-oncol, January 1, 2008; 10(6): 1004 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Schafer-Hales, J. Iaconelli, J. P. Snyder, A. Prussia, J. H. Nettles, A. El-Naggar, F. R. Khuri, P. Giannakakou, and A. I. Marcus
Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function
Mol. Cancer Ther., April 1, 2007; 6(4): 1317 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. I. Marcus, A. M. O'Brate, R. M. Buey, J. Zhou, S. Thomas, F. R. Khuri, J. M. Andreu, F. Diaz, and P. Giannakakou
Farnesyltransferase Inhibitors Reverse Taxane Resistance.
Cancer Res., September 1, 2006; 66(17): 8838 - 8846.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. E. Rusinol and M. S. Sinensky
Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors.
J. Cell Sci., August 15, 2006; 119(Pt 16): 3265 - 3272.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. I. Marcus, J. Zhou, A. O'Brate, E. Hamel, J. Wong, M. Nivens, A. El-Naggar, T.-P. Yao, F. R. Khuri, and P. Giannakakou
The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase
Cancer Res., May 1, 2005; 65(9): 3883 - 3893.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Larghero, N. Gervais, B. Cassinat, J.-D. Rain, M.-H. Schlageter, R. A. Padua, C. Chomienne, and P. Rousselot
Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells
Blood, May 1, 2005; 105(9): 3743 - 3745.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Cortes, S. Faderl, E. Estey, R. Kurzrock, D. Thomas, M. Beran, G. Garcia-Manero, A. Ferrajoli, F. Giles, C. Koller, et al.
Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes
J. Clin. Oncol., April 20, 2005; 23(12): 2805 - 2812.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero, F. Rojo, I. Marimon, M. Voi, J. Albanell, M. Guix, F. Vazquez, J. Carulla, M. Cooper, J. Andreu, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors
J. Clin. Oncol., April 10, 2005; 23(11): 2521 - 2533.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Manne, F. Y. F. Lee, D. K. Bol, J. Gullo-Brown, C. R. Fairchild, L. J. Lombardo, R. A. Smykla, G. D. Vite, M.-L. D. Wen, C. Yu, et al.
Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models
Cancer Res., June 1, 2004; 64(11): 3974 - 3980.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Kurzrock, H. M. Kantarjian, J. E. Cortes, N. Singhania, D. A. Thomas, E. F. Wilson, J. J. Wright, E. J. Freireich, M. Talpaz, and S. M. Sebti
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
Blood, December 15, 2003; 102(13): 4527 - 4534.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. M. Sebti
Blocked Pathways: FTIs Shut Down Oncogene Signals
Oncologist, December 1, 2003; 8(90003): 30 - 38.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Lancet and J. E. Karp
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
Blood, December 1, 2003; 102(12): 3880 - 3889.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. B. Brunner, S. M. Hahn, A. K. Gupta, R. J. Muschel, W. G. McKenna, and E. J. Bernhard
Farnesyltransferase Inhibitors: An Overview of the Results of Preclinical and Clinical Investigations
Cancer Res., September 15, 2003; 63(18): 5656 - 5668.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. B.Y. Ma, R. G. Bristow, J. Kim, and L. L. Siu
Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents
J. Clin. Oncol., July 15, 2003; 21(14): 2760 - 2776.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Shi, J. Gera, J.-h. Hsu, B. Van Ness, and A. Lichtenstein
Cytoreductive Effects of Farnesyl Transferase Inhibitors on Multiple Myeloma Tumor Cells
Mol. Cancer Ther., June 1, 2003; 2(6): 563 - 572.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. B. Lobell, D. Liu, C. A. Buser, J. P. Davide, E. DePuy, K. Hamilton, K. S. Koblan, Y. Lee, S. Mosser, S. L. Motzel, et al.
Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I
Mol. Cancer Ther., July 1, 2002; 1(9): 747 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Lobell, C. A. Omer, M. T. Abrams, H. G. Bhimnathwala, M. J. Brucker, C. A. Buser, J. P. Davide, S. J. deSolms, C. J. Dinsmore, M. S. Ellis-Hutchings, et al.
Evaluation of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Inhibitor Combinations in Preclinical Models
Cancer Res., December 1, 2001; 61(24): 8758 - 8768.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. C. Rose, F. Y. F. Lee, C. R. Fairchild, M. Lynch, T. Monticello, R. A. Kramer, and V. Manne
Preclinical Antitumor Activity of BMS-214662, a Highly Apoptotic and Novel Farnesyltransferase Inhibitor
Cancer Res., October 1, 2001; 61(20): 7507 - 7517.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. A. Adjei
Blocking Oncogenic Ras Signaling for Cancer Therapy
J Natl Cancer Inst, July 18, 2001; 93(14): 1062 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Feldkamp, N. Lau, L. Roncari, and A. Guha
Isotype-specific Ras{middle dot}GTP-Levels Predict the Efficacy of Farnesyl Transferase Inhibitors against Human Astrocytomas Regardless of Ras Mutational Status
Cancer Res., June 1, 2001; 61(11): 4425 - 4431.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Cohen-Jonathan, S. M. Evans, C. J. Koch, R. J. Muschel, W. G. McKenna, J. Wu, and E. J. Bernhard
The Farnesyltransferase Inhibitor L744,832 Reduces Hypoxia in Tumors Expressing Activated H-ras
Cancer Res., March 1, 2001; 61(5): 2289 - 2293.
[Abstract] [Full Text]

Home page
 BloodHome page
D. G. Peters, R. R. Hoover, M. J. Gerlach, E. Y. Koh, H. Zhang, K. Choe, P. Kirschmeier, W. R. Bishop, and G. Q. Daley
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
Blood, March 1, 2001; 97(5): 1404 - 1412.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. W. End, G. Smets, A. V. Todd, T. L. Applegate, C. J. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, S. Skrzat, et al.
Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro
Cancer Res., January 1, 2001; 61(1): 131 - 137.
[Abstract] [Full Text]

Home page
 BloodHome page
C. W. M. Reuter, M. A. Morgan, and L. Bergmann
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
Blood, September 1, 2000; 96(5): 1655 - 1669.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
T. L. Glass, T.-J. Liu, and W.K. A. Yung
Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336
Neuro-oncol, July 1, 2000; 2(3): 151 - 158.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
C. A. Omer, Z. Chen, R. E. Diehl, M. W. Conner, H. Y. Chen, M. E. Trumbauer, S. Gopal-Truter, G. Seeburger, H. Bhimnathwala, M. T. Abrams, et al.
Mouse Mammary Tumor Virus-Ki-rasB Transgenic Mice Develop Mammary Carcinomas That Can Be Growth-inhibited by a Farnesyl:Protein Transferase Inhibitor
Cancer Res., May 1, 2000; 60(10): 2680 - 2688.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
F. Aklilu, J. Gladu, D. Goltzman, and S. A. Rabbani
Role of Mitogen-activated Protein Kinases in the Induction of Parathyroid Hormone-related Peptide
Cancer Res., March 1, 2000; 60(6): 1753 - 1760.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
L. L. Nielsen, B. Shi, G. Hajian, B. Yaremko, P. Lipari, E. Ferrari, M. Gurnani, M. Malkowski, J. Chen, W. R. Bishop, et al.
Combination Therapy with the Farnesyl Protein Transferase Inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in Preclinical Cancer Models
Cancer Res., December 1, 1999; 59(23): 5896 - 5901.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. K. Rowinsky, J. J. Windle, and D. D. Von Hoff
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
J. Clin. Oncol., November 1, 1999; 17(11): 3631 - 3652.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Du and G. C. Prendergast
Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors
Cancer Res., November 1, 1999; 59(21): 5492 - 5496.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Sun, M. A. Blaskovich, D. Knowles, Y. Qian, J. Ohkanda, R. D. Bailey, A. D. Hamilton, and S. M. Sebti
Antitumor Efficacy of a Novel Class of Non-thiol-containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine
Cancer Res., October 1, 1999; 59(19): 4919 - 4926.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Mahgoub, B. R. Taylor, M. Gratiot, N. E. Kohl, J. B. Gibbs, T. Jacks, and K. M. Shannon
In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor on Nf1-Deficient Hematopoietic Cells
Blood, October 1, 1999; 94(7): 2469 - 2476.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Del Villar, J. Urano, L. Guo, and F. Tamanoi
A Mutant Form of Human Protein Farnesyltransferase Exhibits Increased Resistance to Farnesyltransferase Inhibitors
J. Biol. Chem., September 17, 1999; 274(38): 27010 - 27017.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Du, A. Liu, and G. C. Prendergast
Activation of the PI3'K-AKT Pathway Masks the Proapoptotic Effects of Farnesyltransferase Inhibitors
Cancer Res., September 1, 1999; 59(17): 4208 - 4212.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Du, P. F. Lebowitz, and G. C. Prendergast
Elevation of {{alpha}}2(I) Collagen, a Suppressor of Ras Transformation, Is Required for Stable Phenotypic Reversion by Farnesyltransferase Inhibitors
Cancer Res., May 1, 1999; 59(9): 2059 - 2063.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
W. Du, P. F. Lebowitz, and G. C. Prendergast
Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB
Mol. Cell. Biol., March 1, 1999; 19(3): 1831 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Norgaard, B. Law, H. Joseph, D. L. Page, Y. Shyr, D. Mays, J. A. Pietenpol, N. E. Kohl, A. Oliff, R. J. Coffey Jr., et al.
Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) {{alpha}} and TGF{{alpha}}/neu Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis
Clin. Cancer Res., January 1, 1999; 5(1): 35 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Suzuki, J. Urano, and F. Tamanoi
Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
PNAS, December 22, 1998; 95(26): 15356 - 15361.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Suzuki, K. Del Villar, and F. Tamanoi
Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents
PNAS, September 1, 1998; 95(18): 10499 - 10504.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Yonemoto, T. Satoh, H. Arakawa, I. Suzuki-Takahashi, Y. Monden, T. Kodera, K. Tanaka, T. Aoyama, Y. Iwasawa, T. Kamei, et al.
J-104,871, a Novel Farnesyltransferase Inhibitor, Blocks Ras Farnesylation In Vivo in a Farnesyl Pyrophosphate-Competitive Manner
Mol. Pharmacol., July 1, 1998; 54(1): 1 - 7.
[Abstract] [Full Text]

Home page
 Mol. Cell. Biol.Home page
R. E. Barrington, M. A. Subler, E. Rands, C. A. Omer, P. J. Miller, J. E. Hundley, S. K. Koester, D. A. Troyer, D. J. Bearss, M. W. Conner, et al.
A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis
Mol. Cell. Biol., January 1, 1998; 18(1): 85 - 92.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
A. M. Kral, R. E. Diehl, S. J. deSolms, T. M. Williams, N. E. Kohl, and C. A. Omer
Mutational Analysis of Conserved Residues of the beta -Subunit of Human Farnesyl:Protein Transferase
J. Biol. Chem., October 24, 1997; 272(43): 27319 - 27323.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. A. Rowell, J. J. Kowalczyk, M. D. Lewis, and A. M. Garcia
Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo
J. Biol. Chem., May 30, 1997; 272(22): 14093 - 14097.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. L. Zhang, P. Kirschmeier, D. Carr, L. James, R. W. Bond, L. Wang, R. Patton, W. T. Windsor, R. Syto, R. Zhang, et al.
Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I
J. Biol. Chem., April 11, 1997; 272(15): 10232 - 10239.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. J. Casey and M. C. Seabra
Protein Prenyltransferases
J. Biol. Chem., March 8, 1996; 271(10): 5289 - 5292.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. R. Ashar, L. James, K. Gray, D. Carr, S. Black, L. Armstrong, W. R. Bishop, and P. Kirschmeier
Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules
J. Biol. Chem., September 22, 2000; 275(39): 30451 - 30457.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.